First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection
Results suggest one shot could keep Lipoprotein(a) levels lower for nearly a year August 28, 2026 – Findings from a Phase 1 clinical trial led by Cleveland Clinic show a single injection of Kylo-11 produced reductions in...
Read More













